These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 12201856

  • 1. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
    Stewart KA, Neumann PJ.
    Value Health; 2002; 5(5):390-7. PubMed ID: 12201856
    [Abstract] [Full Text] [Related]

  • 2. FDA actions against health economic promotions, 2002-2011.
    Neumann PJ, Bliss SK.
    Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
    [Abstract] [Full Text] [Related]

  • 3. A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.
    Symonds T, Hackford C, Abraham L.
    Value Health; 2014 Jun; 17(4):433-7. PubMed ID: 24969004
    [Abstract] [Full Text] [Related]

  • 4. An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims.
    Chatterjee S, Patel HK, Sansgiry SS.
    Pharm Pract (Granada); 2012 Oct; 10(4):194-8. PubMed ID: 24155837
    [Abstract] [Full Text] [Related]

  • 5. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
    Cowden AL, Katz KA.
    Br J Dermatol; 2006 May; 154(5):950-8. PubMed ID: 16634900
    [Abstract] [Full Text] [Related]

  • 6. Drug Advertising Violations: A Longitudinal Trend Analysis of FDA Enforcement Letters from 2005 to 2019.
    Zagrodney KAP, Sheikhan NY, Pinto A, Sheikhan T, Witek TJ.
    Pharmaceut Med; 2021 Jan; 35(1):31-38. PubMed ID: 33453042
    [Abstract] [Full Text] [Related]

  • 7. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
    Kim H.
    Int J Health Policy Manag; 2015 Aug 25; 4(12):813-21. PubMed ID: 26673465
    [Abstract] [Full Text] [Related]

  • 8. Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model.
    Mohite N, Funtanilla V, Muzumdar J, Park T.
    Innov Pharm; 2021 Aug 25; 12(1):. PubMed ID: 34007685
    [Abstract] [Full Text] [Related]

  • 9. Evaluating promotional claims as false or misleading.
    Brushwood DB, Knox CA, Liu W, Jenkins KA.
    Am J Health Syst Pharm; 2013 Nov 01; 70(21):1941-4. PubMed ID: 24128969
    [Abstract] [Full Text] [Related]

  • 10. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.
    Salas M, Martin M, Pisu M, McCall E, Zuluaga A, Glasser SP.
    Pharmaceut Med; 2008 Mar 01; 22(2):. PubMed ID: 24353430
    [Abstract] [Full Text] [Related]

  • 11. Unsubstantiated health claims for COVID-19 infections are led by cannabidiol: return of snake oil medicine.
    Tran A, Sheikhan NY, Sheikhan T, Nowak DA, Witek TJ.
    J Cannabis Res; 2021 Dec 08; 3(1):49. PubMed ID: 34876238
    [Abstract] [Full Text] [Related]

  • 12. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
    Wagoner KG, Lazard AJ, Romero-Sandoval EA, Reboussin BA.
    Cannabis Cannabinoid Res; 2021 Dec 08; 6(6):559-563. PubMed ID: 34142863
    [Abstract] [Full Text] [Related]

  • 13. The regulation of patient-reported outcome claims: need for a flexible standard.
    Morris LA, Miller DW.
    Value Health; 2002 Dec 08; 5(4):372-81. PubMed ID: 12102699
    [Abstract] [Full Text] [Related]

  • 14. Direct-to-physician and direct-to-consumer advertising: Time to have stringent regulations.
    Kannan S, Gowri S, Tyagi V, Kohli S, Jain R, Kapil P, Bhardwaj A.
    Int J Risk Saf Med; 2015 Dec 08; 27(2):77-83. PubMed ID: 26410010
    [Abstract] [Full Text] [Related]

  • 15. When Does FDAMA Section 114 Apply? Ten Case Studies.
    Neumann PJ, Saret CJ.
    Value Health; 2015 Jul 08; 18(5):682-9. PubMed ID: 26297097
    [Abstract] [Full Text] [Related]

  • 16. Regulation of prescription drug promotion: direct-to-consumer advertising.
    Baylor-Henry M, Drezin NA.
    Clin Ther; 1998 Jul 08; 20 Suppl C():C86-95. PubMed ID: 9915094
    [Abstract] [Full Text] [Related]

  • 17. Examining the FDA's oversight of direct-to-consumer advertising.
    Gahart MT, Duhamel LM, Dievler A, Price R.
    Health Aff (Millwood); 2003 Jul 08; Suppl Web Exclusives():W3-120-3. PubMed ID: 14527243
    [Abstract] [Full Text] [Related]

  • 18. The Tip of the Iceberg of Misleading Online Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Mintzes B.
    Int J Health Policy Manag; 2016 Feb 18; 5(5):329-31. PubMed ID: 27239883
    [Abstract] [Full Text] [Related]

  • 19. Considering the Future of Pharmaceutical Promotions in Social Media Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Carpentier FR.
    Int J Health Policy Manag; 2016 Feb 09; 5(4):283-5. PubMed ID: 27239874
    [Abstract] [Full Text] [Related]

  • 20. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.
    Nguyen D, Seoane-Vazquez E, Rodriguez-Monguio R, Montagne M.
    BMC Health Serv Res; 2013 Jan 22; 13():27. PubMed ID: 23339419
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.